Researchers published data from March 25 in the journal. They evaluated cost-effectiveness, expressed as the incremental cost-effectiveness ratio and secondary outcomes focused on quality of life.
The study found patients were willing to pay an estimated $100,000 for the benefits of the implant, designed to stabilize the spine without fusing, within a year after surgery. The device, which has a $4,000 cost premium over TLIF, also was found to be the dominant strategy after two years.
“Tops appears to be a highly cost-effective surgical modality compared with TLIF as a motion-preserving, nonfusion alternative for the treatment of grade 1 spondylolisthesis with lumbar spinal stenosis,” the study’s lead author, Jared Ament, MD, said in a June 2 news release from Premia Spine. “Since the Tops system yields greater quality of life at a lower total cost over time, it deserves serious attention.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.